Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4238971 | 0.97 | TTR (0.48) | TDP2MAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4234229 | 0.90 | TTR (0.48) | MAPTKMT2AMEN1SMN1; SMN2TTR | |
| SCHEMBL4240320 | 0.89 | ALDH1A1 (0.42) | MAPTKMT2AMEN1ALDH1A1TBXA2R | |
| SCHEMBL4232035 | 0.89 | MAPT (0.46) | MAPTKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4237809 | 0.88 | PDE7A (0.54) | MAPTKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4237489 | 0.88 | TBXA2R (0.41) | MAPTKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL4227934 | 0.88 | HSPB1 (0.53) | TDP2MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL4238047 | 0.88 | TBXA2R (0.48) | MAPTKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL4237866 | 0.88 | MAOB (0.40) | TDP2MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL4236941 | 0.86 | HSPB1 (0.40) | TDP2MAPTKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | TDP2 1999/4885MAPT 1398/4885KMT2A 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.